论文部分内容阅读
Objectives: Elderly Glioblastoma multiforme(GBM) patients have a worse prognosis and receive variable treatments.MGMT gene promoter methylation is linked with improved survival in GBM.We examined treatments administered and survival including in relation to MGMT methylation status in elderly GBM patients.Patients and Methods: Patients ≥65 years with diagnosed GBM between 1/01/2007 and 30/04/2009 and undergoing either a biopsy,subtotal(STR) or gross total resection(GTR) were included.The collected information included MGMT status [methylated(ME) vs.unmethylated(UN)] and survival data.P< 0.05 was considered significant.Results: 59 patients were identified with median age at diagnosis being 72.68 years(65.72-85.04).Treatment included surgery(25 GTR,8 STR,26 biopsy),chemoradiation(22) and radiotherapy alone(20).Overall median overall survival(MOS) was 219 days.MOS with chemoradiation was 316 days vs.143 days without it(P=0.011).47 patients had definite MGMT status(28 ME,19 UN).In ME patients,9/28 received temozolamide compared to 10/19 in UN category.Temozolamide administration in patients with definite MGMT status was based on WHO performance status(P=0.007).MOS in UN group was 308 days vs.167 days in ME group(P=0.068).In a multivariate Cox model including use of temozolamide,WHO score and methylation status,only temozolamide use was significantly associated with a reduced risk for death(HR 0.443,95% CI 0.200-0.982,P=0.045).Conclusions: In this small cohort of patients,chemoradiation in suitable elderly GBM patients seemed to afford a survival benefit.MGMT methylation was not associated with an improved survival with temozolamide being the only factor leading to a better survival.Temozolamide use should be considered irrespective of MGMT status in this population with future large prospective studies needed to elucidate this further.
Objectives: Elderly Glioblastoma multiforme (GBM) patients have a worse prognosis and receive variable treatments. MGMT gene promoter methylation is linked with improved survival in GBM. We examined treatments administered and survival including in relation to MGMT methylation status in elderly GBM patients. Pats. And Methods: Patients ≥65 years with diagnosed GBM between 1/01/2007 and 30/04/2009 and undergoing either a biopsy, subtotal (STR) or gross total resection (GTR) were included. Collected information included MGMT status [methylated ( ME) vs. unmethylated (UN)] and survival data. P <0.05 was considered significant. Results: 59 patients were identified with median age at diagnosis being 72.68 years (65.72-85.04). Treatment included surgery (25 GTR, 8 STR, Overall median overall survival (MOS) was 219 days. Patients with chemoradiation were 316 days vs 143 days without it (P = 0.011) .47 patients had definite MGMT status (28 ME, 19 UN). In ME pati ents, 9/28 received temozolamide compared to 10/19 in UN category. Temozolamide administration in patients with definite MGMT status was based on WHO performance status (P = 0.007) .MOS in UN group was 308 days vs.167 days in ME group (P = 0.068) .In a multivariate Cox model including use of temozolamide, WHO score and methylation status, only temozolamide use was significantly associated with reduced risk for death (HR 0.443, 95% CI 0.200-0.982, P = 0.045). Conclusions: In this small cohort of patients, chemoradiation in suitable elderly GBM patients seemed to afford a survival benefit. GMMT methylation was not associated with an improved survival with temozolamide being the only factor leading to a better survival. Temozolamide use should be considered irrespective of MGMT status in this population with future large prospective studies needed to elucidate this further.